 |
|||
 |
|
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
||||||||||||
|
|||||||||||||
|
|
||||||||||||
|
 Isis’ antisense product pipeline is the Company’s most valuable asset. The Company's goal is to advance multiple antisense drugs in parallel, providing it with many opportunities for clinical success. Isis has successfully commercialized the world’s first antisense drug, Vitravene® and has created a product pipeline with the following characteristics:
To access information on each of Isis' products, their molecular targets and development histories, please visit the product pipeline section of this site. |
|
|
 |
|